Kura Oncology officer proposes $158K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. officer Mollie Leoni gave notice of a proposed sale of 22,241 common shares, with an aggregate market value of $157,688.69 and an approximate sale date of November 17, 2026. She acquired the shares from the issuer as performance stock units on November 13, 2026. The stated Rule 10b5-1 plan adoption or instruction date for the proposed sale is March 19, 2026. Leoni’s prior-three-month sales included 19,009 shares for gross proceeds of $141,485.36 on November 16; 28,802 shares for $309,566.78 on September 29, identified as a 10b5-1 sale; and 12,448 shares for $130,670.01 on September 28.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Performance Stock Units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.